Evidence map›Paper›PMID 19549122›Full record

ArticleBJU international2009

Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sample.

Susan A Hall, Carol L Link, Jim C Hu, Paul W Eggers, John B McKinlay

Abstract read
In one paragraph

Article in BJU international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. The Burden of Overactive Bladder on US Public Health.Current bladder dysfunction reports · 2016
    Article
  9. Cohort profile: the Boston Area Community Health (BACH) survey.International journal of epidemiology · 2014
    Article
  10. Observational
  11. Article
  12. Novel biomarkers for overactive bladder.Nature reviews. Urology · 2011
    Review
  13. Management of overactive bladder.Nature reviews. Urology · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Susan A HallDivision of Urologic Surgery, Brigham and Women's Hospital, Boston, MA, USA. shall@neriscience.com
Carol L Link
Jim C Hu
Paul W Eggers
John B McKinlay

Funding

Trajectories of Urologic Disease: Follow-up of BACHU01DK056842 · NIDDK · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI MCKINLAY, JOHN B · 2001 to 2011
$15.7M
Trajectories of Urologic Disease: Follow-up of BACHR01DK056842 · NIDDK · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI MCKINLAY, JOHN B · 2007 to 2007
$1.2M
NIDDK NIH HHS DK 56842NIDDK NIH HHS R01 DK056842NIDDK NIH HHS U01 DK056842
6 · The paper itself

Abstract

objectiveTo examine, in a community-based sample, the use of prescription drugs for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH), overactive bladder, erectile dysfunction, urinary incontinence, and painful bladder syndrome; and to determine whether the use of recommended medications varied by sociodemographics, symptom severity, access to care, and other factors. SUBJECTS AND

methodsIn a cross-sectional analysis of data obtained from 5503 men and women residents participating in the Boston Area Community Health Survey of Boston, MA, urological symptoms were ascertained by in-person interviews conducted during 2002-2005, using validated symptom scales. Medication use in the past 4 weeks was captured using a combination of drug-inventory methods and self-report.

resultsCompared to the prevalence of symptoms, the prevalence of use of medications for urological conditions was very low among men and women. The highest prevalence of use was among men with moderate-to-severe LUTS/BPH symptoms, where 9.6% used recommended drugs. Use of medications did not vary consistently by race/ethnicity or socioeconomic status, but was often associated with symptom severity. More frequent and more recent use of medical care was also associated with greater use of urological medications.

conclusionsOnly a small proportion of community-dwelling men and women with urological symptoms are receiving recommended effective drug treatments for urological conditions. While not all persons are candidates for drug treatment, our results suggest that there is a substantial unmet need in the general population.

Indexed as

AdultAgedBostonEpidemiologic MethodsFemaleGenital Diseases, MaleHumansMaleMiddle AgedNeeds AssessmentPrescription DrugsUrologic DiseasesPrescription Drugs

Identifiers

PMID19549122
PMCPMC2803331

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.